Nektar Therapeutics
NKTR
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.09B
Close$
$-30.55
140.2% downside
Current Fair Value
140.2% downsideOvervalued by 140.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.09 Billion |
|---|---|
| Enterprise Value | $2.13 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-9.73 |
| Beta | 1.16 |
| Outstanding Shares | 33,054,865 |
Return
| Return on Equity | -17.40% |
|---|---|
| Return on Assets | -14.35% |
| Return on Invested Capital | -13.73% |
Valuation & Multiples
| P/E Ratio | -11.05 |
|---|---|
| PEG | 473.2 |
| Price to Sales | 75.92 |
| Price to Book Ratio | 2.81 |
| Enterprise Value to Revenue | 39.09 |
| Enterprise Value to EBIT | -15.17 |
| Enterprise Value to Net Income | -14 |
| Total Debt to Enterprise | 0.04 |
| Debt to Equity | 0.09 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 13, 2026
EPS Estimate
$-1.97
Average shareholder expectationRevenue Estimate
$10.43 M
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$-1.27
Average shareholder expectationRevenue Estimate
$10.20 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 48.87% |
|---|---|
| Total Calls | 29,000▼ 96.95% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 24.63%▼ 106.91% |
|---|---|
| Total Invested | $425.58M▼ 77.83% |
| Investors Holding | 66▼ 154.00% |
ESG Score
No data
About Nektar Therapeutics
CEO: Howard Robin